WO2004052338A1 - 生体腔洗浄剤、生体腔洗浄装置および生体腔洗浄方法 - Google Patents
生体腔洗浄剤、生体腔洗浄装置および生体腔洗浄方法 Download PDFInfo
- Publication number
- WO2004052338A1 WO2004052338A1 PCT/JP2003/015747 JP0315747W WO2004052338A1 WO 2004052338 A1 WO2004052338 A1 WO 2004052338A1 JP 0315747 W JP0315747 W JP 0315747W WO 2004052338 A1 WO2004052338 A1 WO 2004052338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gas
- body cavity
- liquid
- liquid mixture
- intestinal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000005406 washing Methods 0.000 title claims description 20
- 239000007788 liquid Substances 0.000 claims abstract description 190
- 239000000203 mixture Substances 0.000 claims abstract description 116
- 238000002156 mixing Methods 0.000 claims abstract description 36
- 239000007789 gas Substances 0.000 claims description 92
- 238000004140 cleaning Methods 0.000 claims description 76
- 238000003780 insertion Methods 0.000 claims description 48
- 230000037431 insertion Effects 0.000 claims description 48
- 239000012459 cleaning agent Substances 0.000 claims description 36
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 25
- 239000003599 detergent Substances 0.000 claims description 25
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000000346 sugar Nutrition 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 12
- -1 inorganic alkalis Chemical class 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 238000005192 partition Methods 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 235000013618 yogurt Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000001735 carboxylic acids Chemical class 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920000223 polyglycerol Polymers 0.000 claims description 7
- 241001474374 Blennius Species 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000002518 antifoaming agent Substances 0.000 claims description 5
- 239000002781 deodorant agent Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 4
- 239000003570 air Substances 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 239000001307 helium Substances 0.000 claims description 4
- 229910052734 helium Inorganic materials 0.000 claims description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000035790 physiological processes and functions Effects 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000000417 fungicide Substances 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims 1
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 120
- 210000000936 intestine Anatomy 0.000 abstract description 12
- 230000033001 locomotion Effects 0.000 abstract description 8
- 208000008415 Fecal Impaction Diseases 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 101
- 210000003608 fece Anatomy 0.000 description 33
- 230000013872 defecation Effects 0.000 description 32
- 230000007246 mechanism Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 24
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 238000003860 storage Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000005243 fluidization Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- 239000004088 foaming agent Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 14
- 229920000609 methyl cellulose Polymers 0.000 description 13
- 239000001923 methylcellulose Substances 0.000 description 13
- 235000010981 methylcellulose Nutrition 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000006260 foam Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008991 intestinal motility Effects 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 238000005187 foaming Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000005060 rubber Substances 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 229920002907 Guar gum Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 244000046146 Pueraria lobata Species 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000003736 gastrointestinal content Anatomy 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 238000009223 counseling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 241001634822 Biston Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010056325 Faecaloma Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 210000002388 eustachian tube Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000019553 satiation Nutrition 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000000701 subdural space Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 239000002969 artificial stone Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229940091142 glycerin enema Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/005—Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1064—Large intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/022—Volume; Flow rate
Definitions
- the present invention relates to a body cavity cleaning agent, a body cavity cleaning device, and a body cavity cleaning method, and more particularly, to a measure for improving and preventing a bowel movement defect due to a malfunction state of an intestinal tract as a body cavity.
- the conventional bowel washing method had to be provided with a large-scale liquid feeding mechanism and a drainage treatment mechanism.
- the present invention has been made in view of the above points, and is intended to cope with various defecation disorders.
- the present invention promotes the mixing of the gas-liquid mixture with the contents of the body cavity inside the body cavity, accelerates the contact area between the foreign liquid component and the contents, and cures the hardened contents. Liquefy.
- the present invention promotes the mixing of the gas-liquid mixture with the contents of the intestinal tract inside the intestinal tract, and accelerates the contact area between the exogenous liquid component and the stool to cure the stool. Liquefy.
- the living body cavity of the present invention mainly targets the intestinal tract, but the living body cavity includes the nasal cavity, the ear cavity, the eustachian tube, the oral cavity, the trachea, the bronchi, the esophagus, the stomach, the duodenum, the small intestine, the gallbladder, the biliary tract, the spinal cord, and the spinal cord.
- Cavity, subdural space, thoracoabdominal cavity, pericardial cavity, mediastinum, renal pelvis, ureter, vesicoureteral cavity, child vaginal cavity, joint cavity, abscess cavity, infectious lesions, abscess and vascular cavity Clearly, a case in which the intestinal tract is targeted as a body cavity will be described below.
- the use of the gas component together with the liquid component reduces the amount of liquid component injected into the intestinal tract.
- the increase in the total amount of liquefied feces-containing waste is suppressed.
- foaming the gas-liquid mixture promotes fluidization of the contents of the intestinal tract, and mechanically injects or discharges exogenous components while avoiding a local or sudden increase in intestinal pressure. And make it possible to respond to various defecation disorders.
- the gas component of the gas-liquid mixture as the developing medium it is preferable to use a gas that is inert and does not cause a risk of vessel occlusion.
- a gas that is inert and does not cause a risk of vessel occlusion is carbon dioxide (C02).
- C02 carbon dioxide
- Examples of the source of C02 include dry ice, C02 generated by a chemical reaction or an exothermic reaction, a C02 cylinder or a C02 spray can.
- the fluidization accelerator for fecal matter which is the content of the intestinal tract, is a fluidizing agent that is harmless to the living body, various polysaccharides, rubbers, saccharide esters, fatty acid esters, salts, amino acids, In addition to peptides and proteins, solutions of these aggregates can be mentioned.
- a safety retention mechanism for adjusting the introduction pressure and the introduction amount of the liquid component to be introduced into the intestinal tract and the gas component as the developing medium may be added.
- the gas-liquid mixture promotes the mixing of intestinal feces with the fluidizer and the liquefaction of feces, and promotes the dispersion of physical feces in the intestinal tract.
- the intestinal lavage apparatus which is a body cavity cleaning apparatus, may include a controller having a selection switch of a flow path for controlling the flow of C02 and the fluidizing agent into the intestine and the defecation.
- the intestinal tract cleaning device may include a deodorizing exhaust system for eliminating odors from the discharged gas.
- a container for separating and collecting the discharged gas component and liquefied stool may be provided.
- the intestinal tract cleaning device may be configured as a device used only once, a disposable package or a device used multiple times.
- the intestinal cleaning device may have a monitor record of the operation of the device in order to determine the optimal operating conditions for each individual.
- the intestinal lavage apparatus may have a time monitor recording system as a progress pacemaker of the operation process. It is preferable to refer to past favorable conditions when performing a plurality of treatments.
- the places where the above-mentioned intestinal cleaning device is installed include hospitals, clinics, beauty salons, and dedicated service stations.
- the mobile intestinal cleaning device is of the on-board type or the portable type, and is used for visiting care and group homes. These may be made into a regional network, and the simple kit intestinal cleaning device is intended for use in private homes.
- the biological cavity cleansing agent of the first invention is composed of a gas-liquid mixture formed by mixing at least a gas component and a liquid component.
- the gas-liquid mixture is constituted by a vapor in which a liquid component is suspended in a gas component.
- the gas-liquid mixture is in a bubble state in which gas is trapped in a liquid. It is configured as follows.
- the fourth invention is configured such that the gas-liquid mixture has a property of fluidizing or dispersing the contents of a living body cavity.
- the gas component of the gas-liquid mixture is a gas containing at least one of air, oxygen, nitrogen, carbon dioxide, argon, and a helium.
- the liquid component is composed of any one of an aqueous solution, an oily liquid, an amphoteric liquid, and an aqueous oily mixture.
- the solute component of the above-mentioned gas-liquid mixture is produced by using celluloses, peronic acids, starch and starch derivatives, dextrins, lactic acid bacteria yogurt and yogurt derivatives, mucopolysaccharides, rubbers, and polysaccharides.
- the composition is at least one selected from bactericides, deodorant adsorbents, oligosaccharides and monosaccharides, electrolytes, inorganic alkalis, and carboxylic acids.
- the gas-liquid mixture contains at least one of bacteria, a constituent material of a solution of a bacterium-producing substance, and carboxylic acids, and a C02 generator.
- the eighth invention is configured such that the gas-liquid mixture contains at least one of a biological component and a physiological function modifier.
- a living body cavity cleaning device is a living body cavity cleaning device comprising an insertion means inserted into a living body cavity, and a gas-liquid mixture formed by mixing at least a gas component and a liquid component.
- Cleaning means for storing the living body cavity cleaning agent from the raw material components of the gas-liquid mixture, and supplying the living body cavity cleaning agent to the insertion means.
- a tenth aspect of the present invention includes a discharging means connected to the insertion means for recovering the contents of the living body cavity discharged from the living body cavity.
- the cleaning means includes a capacity control means for controlling a supply amount of the body cavity cleaning agent.
- the cleaning means is provided in a flexible container and provided in the container. And a breakable partition for partitioning the inside of the container into a plurality of sections.
- the gas-liquid mixture is formed in a bubble state in which a gas is confined in a liquid.
- a living body cavity cleaning method provides a living body cavity cleaning agent comprising an insertion means inserted into a living body cavity and a gas-liquid mixture formed by mixing at least a gas component and a liquid component. Storing the living-cavity cleaning agent from the raw material components of the gas-liquid mixture, and supplying the living-body cavity cleaning agent to the insertion means; inserting the insertion means into the living body cavity; It is configured that the living body cavity cleaning agent is injected into the body cavity through the insertion means from the above cleaning agent means.
- the contents of the living body cavity discharged from the living body cavity to the discharging means connected to the insertion means are collected. It has a configuration.
- the sixteenth invention is configured such that the supply amount of the living body cavity cleaning agent is controlled by a capacity control unit connected to the connection unit.
- a seventeenth invention is configured such that the gas-liquid mixture is in a bubble state in which a gas is confined in a liquid.
- the eighteenth invention is configured such that an antifoaming agent is administered to the living body cavity in a washing process after the living body cavity cleaning agent is injected into the living body cavity.
- the living body cavity is cleaned by the above configuration. Therefore, cleaning of the intestinal tract will be described below.
- defecation disorders involve intestinal spasm, decreased motility, decreased fluidity and solidification of intestinal stool.
- the water content of stool is 70% or more even for hardened stool, and if it exceeds 80%, diarrhea is considered to be stool.
- no additional water is required for liquefaction of the soil observed during an earthquake. Therefore, in order to excrete the fecal impaction, it is important to give the hardened stool, etc., a property of fluidization and to be easily discharged without adding much water.
- the intestinal tract can be expanded to expand and dilate the intestinal tract, giving the intestinal smooth muscle a physical trigger for contraction, and lubricating molecules in the gap between the intestinal wall and the stool. Entering is also useful.
- a gas-liquid mixture composed of a gas component and a liquid component is applied.
- This gas component may be steam.
- the intestinal tract is extended and the stool and the large intestinal wall are dissociated.
- the stool is changed into a slippery state or a form that is easily excreted by liquefied vapor deposition of water or the like or by a substance contained in the gas-liquid mixture.
- the dilation stimulates the motor function of the intestinal tract to promote excretion of feces.
- wax, silicon, etc. enter the gap between the contents of the intestinal tract and the intestinal wall and deposit on the interface to facilitate defecation, and the injection of gas molecules and their clusters with high kinetic energy Promotes collapse of the stool interface.
- the intestinal tract is extended, and the stool and the large intestine wall are dissociated.
- fluidizing components and the like contained in the gas-liquid mixture make the feces easy to slip and excrete, and the capacity expansion stimulates the motor function of the intestinal tract to promote the excretion of feces.
- it promotes excretion of feces by extending the colon and dissociating and fluidizing feces from the intestinal wall by liquid and gas in the large intestine, and by increasing intestinal motility.
- the combined infusion of liquid and gas can prevent excessive intestinal internal pressure, preventing pain and discomfort and ensuring the safety of the procedure .
- a gas-liquid mixture in a foamed state is injected into the intestinal tract, thereby extending the intestinal tract and dissociating the stool and the large intestinal wall.
- a slight increase in pressure causes a large volume of the gas-liquid mixture to be distributed in the intestinal tract, in addition to the liquid. Therefore, it can safely and efficiently expand the lumen of the large intestine and dissociate and disperse the contents (impacts) from the intestinal tract wall, activate the intestinal motility, and induce excretion of the feces.
- the gas-liquid mixture is formed into a bubble, uniform and wide distribution of the fluidizing agent can be achieved. When the gas is wrapped in a solution with a high viscosity or a low surface tension, the gas-liquid mixture will show bubbles.
- the gas-liquid mixture is formed outside the body by mixing a gas at normal pressure or a gas compressed in a cylinder with a solution. In addition, gas is released into the solution to form a gas-liquid mixture containing air bubbles in the closed cavity.
- gas-liquid mixture may be one in which gas and liquid are compressed and stored in a cylinder.
- the gas-liquid mixture is formed by mixing a liquid or solid phase of a molecule exhibiting a gas phase at normal temperature and normal pressure with a solution.
- a substance in a solid phase is placed in a solution, and a gas-liquid mixture containing bubbles is formed by vaporization or sublimation.
- the gas-liquid mixture is formed by shaking a gas and a liquid. Further, the gas-liquid mixture forms a gas in a solution by a physicochemical reaction.
- the gas-liquid mixture is formed by mixing a gas generated by heating or combustion with a solution.
- the gas-liquid mixture is formed by adding a gas in addition to the liquid put into the intestinal tract.
- the gas-liquid mixture is formed by promoting gas release by a chemical reaction in a liquid placed in the intestinal tract.
- the gas-liquid mixture is formed by supplying a liquid to a chemical reaction substrate which is provided in the intestinal tract and emits gas.
- the gas-liquid mixture is formed by mixing a liquid in addition to the gas introduced into the intestinal tract.
- bubble formation occurs in which the internal pressure of the bubble and the liquid tension oppose each other.
- bubbles are formed by blowing a gas into a liquid, like forming a soap bubble.
- the mixing of gas and liquid includes the introduction of gas from the nozzle, generation of continuous gas, a mixing chamber that introduces both gas and liquid, and subdivision of gas-liquid mixture. And a mesh-like passage mechanism that causes the formation.
- the water content of stool is more than 70% even for hardened stool. Therefore, in order to excrete feces, it is important that hardened stools and the like are given the opportunity to fluidize and be easily discharged without adding much water.
- a substance having physical properties that promote specific or non-specific dispersion or fluidization of an intestinal substance is administered. As a result, a treatment that improves, prevents, or alleviates constipation can be performed without using a large-volume solution and suppressing an increase in intestinal internal pressure.
- gaseous elements and molecules including air, oxygen, nitrogen, carbon dioxide, argon, and helium, and a mixed gas thereof are used as gaseous components.
- it when introduced into the intestinal tract, it is preferably in an inactive state that is less likely to cause a chemical reaction and has little effect on the activity of living cells. Further, carbon dioxide having a high solubility in blood and a low risk of emboli is preferable.
- any of an aqueous solution, an oily liquid, an amphoteric liquid, and an aqueous oily mixture may be used as long as the foaming of the feces accelerates the development into the intestinal tract.
- a substance having high biocompatibility for example, an emulsifier such as a sugar ester imparting smoothness, such as celluloses including methylcellulose, which increases the viscosity of the solution, and polybutyl alcohol.
- an emulsifier such as a sugar ester imparting smoothness, such as celluloses including methylcellulose, which increases the viscosity of the solution, and polybutyl alcohol.
- Natural stones or synthetic stones that do not damage the mucous membrane are preferred.
- solute components methylcellulose, pectin, dextrin, guar gum, polyvinyl alcohol, sugar ester, polyglycerol, polyethylene glycol, glycerin, kuzu, starch and starch-based products, coconut Natural and synthetic oils such as oil, castor oil and rapeseed oil; surfactants such as tyloxapol; various detergents; fragrances such as menthol, mint, spearmint, lavender, phyton and cedrol; bactericides such as hinokitiol; activated carbon; Any of the deodorant adsorbent, oligosaccharide, monosaccharide, and lactic acid bacteria preparation, or a combination thereof is preferable.
- Carboxylic acids include monocarboxylic acids such as lactic acid, dicarboxylic acids such as tartaric acid, and tricarboxylic acids such as citric acid.
- the herb milk thistle enhances the detoxifying effect of the liver
- the birdock is used to enhance the function of both the kidney and liver.
- These can be used alone or in an appropriate combination of two or more.
- the combination of methylcellulose and the like with an ester agent promotes foaming and mixing and fluidization with feces.
- methylcellulose usually 0.01 to 5 w / V% is preferably used in the composition
- cyclodextrin usually 0.01 to 5 w / V% is used in the composition.
- the amount of the polymer compound is too small, the wettability of the stool in the intestinal tract becomes insufficient, so that fluidization of the stagnant stool may not be sufficiently obtained. If the amount of the polymer compound is too large, the viscosity may be too high and the inflow operation into the intestine may be uncomfortable.
- Various additives such as a tonicity agent, a stabilizing agent, a thickening agent, a chelating agent, a pH adjusting agent, a cooling agent, and other pharmaceutically active ingredients can be blended.
- examples of the buffer include boric acid or a salt thereof (borax or the like), citric acid or a salt thereof (sodium citrate), phosphoric acid or a salt thereof (monohydrogen phosphate) Sodium), tartaric acid or a salt thereof (such as sodium tartrate), dalconic acid or a salt thereof (such as sodium dalconate), acetic acid or a salt thereof (such as sodium acetate), lactic acid or a salt thereof (sodium lactate) And various amino acids and the like, and combinations thereof.
- Dissolution aids include small amounts of polyethylene glycol and propylene glycol And the like.
- tonicity agent examples include sodium chloride, chlorine chloride, mannitol, propylene dalicol and the like.
- the stabilizer examples include sodium edetate, cyclodextrin, sulfite, citrate or a salt thereof, and the like.
- thickener examples include polyethylene dalicol, polyvinyl alcohol, polyvinylinolepyrrolidone, hydroxyxetinoresenolerose, hydroxypropinolemethylcellulose, methylcellulose, sodium chondroitin sulfate, and the like.
- Examples of the chelating agent include sodium edetate, sodium citrate and the like.
- Examples of the pH adjuster include hydrochloric acid, citric acid or a salt thereof, boric acid or a salt thereof, phosphoric acid or a salt thereof, acetic acid or a salt thereof, tartaric acid or a salt thereof, sodium hydroxide, sodium hydroxide, Examples include sodium carbonate and sodium hydrogen carbonate.
- cooling agent examples include menthol, borneol, camphor, geraniol, limonene, eugenol, heart oil, eucalyptus oil and the like.
- the intestinal cleansing agent of the present invention usually has a pH of 4 to 9.
- the dose is not particularly limited as long as it is medically acceptable.
- the intestinal cleansing agent of the present invention is preferably administered several times repeatedly in a single dose spread in C02 of 30 to 500 ml.
- the volume of feces for a standard adult at a time is 300 ml
- the water content is 70% for normal stool and 85% for diarrhea stool.
- Amount is 45 m 1.
- This volume is used as a standard, and it is injected into the body cavity as bubbles or a gas-liquid mixture in a gas of about 300 m1 in consideration of age, gender and health condition. An injection time of 5 minutes to 1 minute is appropriate, so the injection speed is about l to 5 m1 / sec.
- the injection pressure into the body cavity is usually within 0.5 m of water and does not exceed a maximum of 1.4 m. Since the volume of the gas is inversely proportional to the pressure, it takes time to increase the pressure unless the injection speed is incorrect. For example, for a gas of 100 m 1, it takes 5 seconds to increase the pressure of the water column 0.5 m (0.05 atm) at an injection rate of 1 m 1 / sec. Injection At times, the sum of the gas such as the injection pipe and the air such as the discharge pipe is more than that, so that a rapid pressure rise can be avoided. As a result, the intestinal lavage of the present invention has higher safety than the conventional rinsing method using an incompressible liquid.
- an inert gas such as C02
- C02 For cleaning the intestinal tract, it is preferable to use an inert gas such as C02, and it is preferable to maintain an environment that provides good intestinal bacterial flora. Therefore, in the seventh invention, since baking soda and yogurt products are mainly introduced into the intestinal tract, both inert and safe generation of C02 and an optimal intestinal environment can be obtained at once.
- an active substance or the like can be introduced into the body.
- various foods contain bacteria and artificial additives (preservatives, colorings, flavors) and food-related substances (such as components dissolved from coated paper).
- chemicals such as environmental solvents and dioxins enter the body. Intestinal washes are an opportunity to adsorb and remove toxic substances adhering to the intestinal tract or circulating in the intestinal tract, and an opportunity to inject antidote and active substances into the body through the transmucosal membrane.
- organs such as kidney, liver, lung, and intestine have their detoxification and excretion and activation functions
- various nucleic acids, amino acids, peptides, proteins, etc. Injecting active substances can enhance the body's physiological functions as well as detoxify it.
- the intestinal lavage and extension are achieved, a favorable environment for absorbing active substances and nutrients from the entire intestinal mucosa is realized, so that not only effects on the intestinal tract but also systemic administration are required. It is one of the most suitable means of transporting the required substances.
- individuals who have difficulty in ingestion have the opportunity to have adequate nutrition, enhanced immunity, and enhanced bioactivity.
- nucleic acids particularly RNA
- nucleic acids, amino acids, peptides, proteins, and the like also have an effect of causing air bubble formation.
- the discharge means since the discharge means is provided, it is possible to promote good defecation.
- the intestinal tract when the intestinal tract is dilated and the stool is fluidized, the retained stool flows out spontaneously.However, in a human body with a spontaneous intestinal motility function decline, even when the stool is fluidized in the intestinal tract, May lack the ability to defecate.
- negative suction, external injection and suction of the contents of the intestinal tract including intestinal washes Defecation can be achieved by adding various means of discharge, such as head massage and ultrasonic irradiation.
- the excrement is released when defecation is caused, it is inconvenient for odor and disposal, so that it is preferable to provide an opening / closing means. It is preferable that the effluent is guided to a power system for collecting in a closed container, a toilet, a sewage system or a piping system to a septic tank.
- a power system for collecting in a closed container, a toilet, a sewage system or a piping system to a septic tank.
- the treatment of distributing substances that cause specific or non-specific fluidization of intestinal components from the stool surface in the large intestine to the inside of the stool requires treatment for constipation, defecation while ensuring rest after surgery, and various bowel diseases. Useful as a workaround.
- the distribution of the infusate in the intestinal tract may occur, and not only the intestinal contents are discharged but also the intestinal tract by auxiliary means such as reflux, injection, repetitive in / out, and vibration of the infusate. Promote distribution and fluidize retained flights.
- the processing operation can be performed cleanly by keeping the defecation in the closed cavity and activating the operation or the device for storing the defecation in the processing container through the conduit by the reflux means. Emissions are reduced by absorbing gas components and separating them from liquid components by releasing them into the atmosphere.
- the supply amount is controlled by the capacity control means.
- the capacity control means For example, rather than injecting foreign substances into the intestinal tract at once, rather than injecting a small amount by means of steady flow, vortex flow, injection or pulsatile flow, or preset pressure / pressure or volume setting, etc. In the intestinal tract, draw more. This will gradually fill the intestinal tract with the infusate. This process has the effect of allowing the intestine to open slowly and easily pass through the feces even in people with difficult constipation.
- the intestinal tract is extended and expanded with a gas-liquid mixture in a foam state, and after the contents of the intestinal tract are fluidized, the intestinal tract is discharged outside the body.
- the amount of injection into the intestinal tract, the speed, the number of repetitions, and the order must be adjusted. It is required that it can be set arbitrarily. Therefore, tailor-made intestinal irrigation can be achieved by blending and using the infusion components that are divided into several conversions.
- a simplified device can be provided.
- the compressed gas and the liquid are housed integrally in a container made of plastic or rubber through a partition that can be easily broken. Then, the gas-liquid mixture is formed by the destruction of the partition walls. Therefore, when the container is inserted into the rectum in advance and opened in the intestinal tract at the tip of the container, the gas-liquid mixture is spread into the intestinal tract to fluidize the feces.
- a configuration may be adopted in which the gas and the liquid are mixed by integrating the gas supply material storage unit and the liquid storage unit into two separate parts.
- the gas-liquid mixture is formed in the folded bag, a sufficient amount of intestinal infusion is obtained in the extended bag when gas is generated. Adjustment for injection into the intestinal tract may be performed.
- the injectate contains nonionic surfactants, viscous substances, and fluidizing substances, so that liquefaction of feces is easily brought about. If the injectable storage part is made to be extensible, it can be used for storing both injectate and discharge through suction expansion.
- the antifoaming agent since the antifoaming agent is added, the treatment after excretion becomes easy. In other words, once the intestinal lavage infusion has fluidized the feces, the presence of air bubbles is no longer essential for defecation guidance. At this time, if the gas and liquid components are separated by using an antifoaming agent, the intestinal contents are easily separated from the gas with the elimination of bubbles, so that the intestinal contents can be easily processed after excretion. Therefore, it is preferable to determine the use of an antifoaming agent in consideration of the feeling of abdominal bloating during the cleaning process.
- evaluation may be performed using the excreta from the intestinal tract, cells or components derived therefrom as a sample, or the cytoplasm and genotype using the intestinal infusate may be evaluated.
- Stool tests are performed for various intestinal evaluations.
- numerous food-borne contaminants in the stool prevent accurate and sensitive determinations.
- contaminants reduce both sensitivity and specificity in the detection of human hemoglobin.
- a substance having a binding ability and a blocking material are introduced into the degenerated site, and endoscopically or via a chemical reaction such as fluorescence, isotope, or enzyme. It can be identified from outside the body.
- the feces are softened and the intestinal tract is expanded, and it is preferable that normal intestinal function is maintained after washing. Therefore, oral depletion of water or fibrous material such as an isotonic solution, an intestinal motility enhancer, etc. before and after the intestinal washing may make defecation by the intestinal washing easier and more effective. It is also effective to use abdominal massage before, during, and after defecation treatment.
- a device for processing intestinal feces by ultrasonic waves, shock waves or physical vibration, and a vibration output terminal may be provided.
- a bubble ruptures, it generates strong shock wave energy in a small area. Therefore, the feces in the intestinal tract, and
- shock waves or physical vibrations from inside or outside the intestinal tract that cause the dispersion and fluidization of the aqueous / liquid mixture such as aqueous solution or air bubbles, the impact of the impacted feces is facilitated and the feces are easily discharged by fluidization. To induce. Therefore, cleaning the intestinal tract has a further effect.
- a service business form including patrols and business trips that provide intestinal cleaning and accompanying treatment, a leasing business that lends business to a third party, and a franchise business that contracts to a third party.
- performing effective and simple intestinal washing at home has problems in terms of manpower, equipment, and the skill of the practitioner.
- homes and facilities may be visited, or a satellite established locally may be used to perform the task of providing gastrointestinal irrigation and associated treatment with a gas-liquid mixture.
- the equipment system can be configured to be simple and secure, so it can be installed on a car or manufactured as a portable type, and can provide on-site services to individual homes and nursing homes.
- Specific examples include the location of equipment or utensils and accessories in less than a fraction of the space required by conventional customers on the lying bedside of serviced customers, waste treatment systems including toilets, and Provide working space for treatment workers.
- the gas and liquid components are categorized as being prepared in individual packages or intensively prepared.
- a gas-liquid supply source and a bowel treatment system are prepared for each of a plurality of subjects, and gas-liquid is supplied to a plurality of subjects via a pipe in a unified manner. Or perform a combined defecation process.
- a gas-liquid mixture composed of a gas component and a liquid component is used, a bedridden person or a person after surgery having intestinal motility dysfunction, a young and middle-aged woman with constipation, etc. It can provide low burden, safe and reliable defecation for people with multiple causes of defecation. Fecal bowel movements cause anorexia due to satiation and may cause various physical illnesses due to decreased physical strength and resistance.However, according to the present invention, various useful components can be effectively injected into the intestinal tract in addition to intestinal lavage. It also contributes to the improvement of biological functions. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a schematic cross-sectional configuration diagram showing an intestinal tract cleaning device according to Embodiment 1 of the present invention.
- FIG. 2 is a flowchart showing the cleaning operation of the first embodiment.
- FIG. 3 is a schematic cross-sectional configuration diagram illustrating an intestinal tract cleaning device according to Embodiment 2 of the present invention.
- FIG. 4 is a schematic cross-sectional configuration diagram showing the intestinal tract cleaning device of Embodiment 2 when the intestinal contents are discharged.
- FIG. 5 is a schematic configuration diagram of a main part showing an intestinal tract cleaning device according to Embodiment 3 of the present invention.
- FIG. 6 is a schematic configuration diagram of a main part of the intestinal cleaning device of the third embodiment when an intestinal cleaning agent is injected.
- FIG. 7 is a cross-sectional front view showing an intestinal tract cleaning apparatus according to Embodiment 4 of the present invention
- (B) is a cross-sectional side view showing an intestinal cleaning apparatus of Embodiment 4 of the present invention.
- FIG. 8 is a flowchart showing a cleaning operation using the intestinal tract cleaning apparatus of the first embodiment.
- FIG. 9 is a table showing characteristics of the intestinal cleansing agent of Example 1.
- FIG. 10 is a table showing the characteristics of the intestinal cleansing agent of Example 2.
- FIG. 11 is a table showing characteristics of the intestinal cleansing agent of Example 3. BEST MODE FOR CARRYING OUT THE INVENTION
- the intestinal lavage device 1 is a body cavity cleaning device, in which an intestinal lavage agent as a body cavity cleanser is injected into the intestinal tract 12 of the body 11 to clean the intestinal tract 12. It is a device for The intestinal cleaning device 1 includes a supply mechanism 2, an insertion jig 3, and a discharge mechanism 4.
- the supply mechanism 2 constitutes a cleaning means for generating an intestinal cleaning agent of a gas-liquid mixture.
- the supply mechanism 2 includes a gas generator 21, a cleaning agent container 22, and a mixer 23.
- the gas generator 21 is configured to generate and store a gas component of the gas-liquid mixture.
- An example of the gas component is C02 (carbon dioxide).
- the gas generator 21 is composed of a C02 cylinder or the like, and is connected to the mixer 23 via the conduit 2a.
- the conduit 2a is provided with a shutoff valve 2b and is connected to a pressure gauge 2c.
- the shutoff valve 2b is a valve that performs the flow of gas components and prevents the flow of the gas components, and opens or closes the conduit 2a.
- the cleaning agent container 22 is configured to store a liquid component of the gas-liquid mixture.
- the gas component includes, for example, an aqueous solution.
- the cleaning agent container 22 holds the intestinal cleaning agent at a predetermined temperature, for example, around 37 degrees Celsius.
- the cleaning agent container 22 is connected to the mixer 23 via a conduit 2d.
- the conduit 2d is provided with a shut-off valve 2e.
- the shut-off valve 2e is a valve for flowing and preventing the flow of the liquid component, constitutes a measuring section for measuring the detergent to be injected into the intestinal tract 12, and opens or closes the conduit 2a.
- the mixer 23 is configured to mix the gas component of the gas-liquid mixture from the gas generator 21 and the liquid component of the gas-liquid mixture from the cleaning agent container 22.
- the mixer 23 includes a stirrer 2 g provided in a stirring space 2 f, and forms a gas-liquid mixture in a bubble state in which gas is trapped in a liquid in the stirring space 2 f.
- the mixer 23 is connected to the insertion jig 3 via a conduit 2h.
- the conduit 2h is provided with a shut-off valve 2i.
- the shut-off valve 2i performs the flow of the intestinal cleanser and the flow thereof.
- the mixer 23 is provided with a pressure and capacity control unit 24.
- the control section 24 is composed of, for example, a piston or the like, and constitutes a volume control means for controlling the injection pressure and the injection amount of the intestinal cleansing agent to be injected into the intestinal tract 12.
- the insertion jig 3 is inserted into the intestinal tract 12 and includes a cylindrical main tube 31 and a sub-tube 32 connected to the main tube 31.
- the distal end of the main pipe 31 is formed into a thin wall, and is configured as an insertion cylinder 3a inserted into the cavity.
- the auxiliary pipe 32 has a distal end connected to the central portion of the main pipe 31 and is inclined obliquely from the rear end to the distal end of the main pipe 31.
- a mixer 23 is connected to a rear end of the auxiliary pipe 32 by a conduit 2 h.
- a discharge mechanism 4 is connected to the rear end of the main pipe 31.
- the discharge mechanism 4 constitutes a discharge means for collecting the contents of the intestine 12 with the excrement from the intestine 12.
- the discharge mechanism 4 includes a discharge pipe 41, a storage section 42, and a suction section 43.
- the discharge pipe 41 is formed in a bellows shape, and one end is connected to the rear end of the main pipe 31 of the insertion jig 3.
- the storage section 42 includes a small-diameter connection cylinder 4a connected to the other end of the discharge pipe 41, and a large-diameter storage cylinder 4b connected to the connection and the like.
- the suction section 43 is provided in the storage cylinder 4b, and is made of, for example, a piston.
- the suction unit 43 is configured to forcibly collect the excrement that is the content of the intestinal tract 12 by setting the inside of the storage cylinder 4b to a negative pressure.
- step ST1 the gas component of the gas-liquid mixture is generated by the gas generator 21.
- step ST2 the gas component is stored.
- step ST3 the cleaning agent container 22 contains a liquid component of the gas-liquid mixture, and the liquid component is kept at, for example, about 37 degrees Celsius.
- the three closing valves 2 b, 2 e, and 2 i of the supply mechanism 2 are in the closed state. It is in.
- step ST4 the amount of the liquid component injected into the body 11 is measured by opening and closing the closing valve 2e, and is supplied to the mixer 23.
- the gas component of the gas-liquid mixer 23 is also supplied to the mixer 23.
- step ST5 the liquid component and the gas component of the gas-liquid mixture are stirred by the stirrer 2 g in the stirring space 2f of the mixer 23 to generate bubbles, and the gas-liquid mixture in the bubble state is formed.
- a mixed intestinal cleanser is produced.
- the pressure and the volume of the intestinal cleansing agent are controlled by the control unit 24, and the inflow of the intestinal cleansing agent flows into the insertion jig 3 via the conduit 2 h by opening the closing valve 2 i of the mixer 23.
- step ST7 the intestinal irrigant flows from the auxiliary tube 32 of the insertion jig 3 to the main tube 31 and is injected into the intestinal tube 12.
- the pressure and volume of the intestinal cleansing agent are adjusted by the control unit 24.
- the intestinal cleaning agent injected into the intestinal tract 12 liquefies the contents of the intestinal tract 12 in step ST8.
- air bubbles enter between the intestinal tract 12 and the contents and promote fluidization and liquefaction of the contents of the intestinal tract 12.
- step ST9 the process proceeds to step ST9, and after a few minutes to several tens of minutes have elapsed after the intestinal cleansing agent was injected, the insertion jig 3 was removed and defecation was performed, or the discharge tube 41 attached to the insertion jig 3 was discharged. Defecate naturally.
- the storage section 42 is made to have a negative pressure by the suction section 43 to discharge the liquefied contents out of the intestinal tract 12. The discharged contents are collected in storage cylinder 4b.
- the foamed gas-liquid mixture may be washed away with an isotonic solution containing a cooling agent.
- Intestinal tract cleaning agent The intestinal cleansing agent of the gas-liquid mixture used in the intestinal cleaning device 1 is preferably an acidic solution (20 ml: 1% methylcellulose, 50% yogurt supernatant, 10% citric acid) and sodium bicarbonate water (5% sugar ester 5 m 1, saturated sodium bicarbonate solution at 20 ° C 12 m 1), and good air bubbles of 550 m 1 are slowly formed. Methylcellulose in this intestinal irrigant causes foam formation and slows down the reaction rate, and sugar ester helps uniform and good microbubble formation.
- the intestinal cleansing agent is constituted by a gas-liquid mixture formed by mixing at least a gas component and a liquid component.
- the gas-liquid mixture may be composed of a vapor in which a liquid component is suspended in a gas component.
- the gas-liquid mixture is preferably formed in a bubble state in which a gas is confined in a liquid.
- the gas-liquid mixture may have properties to fluidize or disperse the contents of the intestinal tract.
- the gas component of the gas-liquid mixture may be a gas containing at least one of air, oxygen, nitrogen, carbon dioxide, argon, and a helium
- the liquid component of the gas-liquid mixture is It may be composed of any one of a liquid, an aqueous solution, an oily liquid, an amphoteric liquid and an aqueous oily mixture.
- the solute components of the gas-liquid mixture include celluloses, peronic acids, starch and starch derivatives, dextrins, lactic acid bacteria yogurt and jordart derivatives, mucopolysaccharides, rubbers, polyvinyl alcohol, polyvinylpyrrolid. Don, sugar ester, polyglycestenole, polyethylene glycol, glycerin, kudzu, seaweeds and seaweed derivatives, natural and synthetic oils, detergents, herbal fragrances, natural and synthetic fungicides, deodorant adsorbents, oligos It is at least one selected from sugars and monosaccharides, electrolytes, inorganic alkalis, and carboxylic acids.
- the raw material of the gas-liquid mixture may include at least one of bacteria, constituents of a solution of a substance producing bacteria and carboxylic acids, and a C02 generator.
- the gas-liquid mixture may contain at least one of a biological component and a physiological function modifier. Effect of one embodiment 1
- a bedridden person or postoperative person with intestinal dyskinesia a young and middle-aged woman with constipation is composed of a gas-liquid mixture composed of a gas component and a liquid component. It can provide low burden, safe and reliable defecation for people with multiple causes of defecation.
- bowel movement may cause anorexia due to satiation and may cause various physical disorders due to decreased physical strength and resistance
- various useful ingredients are effectively applied to the intestinal tract as well as intestinal lavage. It can be injected and contributes to the improvement of biological functions.
- the insertion cylinder 3a of the insertion jig 3 may be provided with a tapered guide head 33, as shown by the broken line in FIG.
- the guide head 33 facilitates insertion into the intestinal tract 12 and is configured to be removed after insertion.
- a simple supply mechanism 5 is formed.
- the supply mechanism 5 includes a container 51 for storing an intestinal irrigant, and a piston 52 provided in the container 51.
- a storage space 5a having an open upper portion is formed in the storage container 51.
- the piston 52 is inserted into the storage space 5a, and is configured to push out the intestinal cleansing agent in the storage space 5a.
- the storage container 51 has a supply passage 5b and an air release passage 5c communicating with the storage space 5a.
- the supply passage 5b is provided with a closing valve 5d, while the air bleeding passage 5c is provided with an air bleed valve 5e.
- the supply passage 5b is connected to the insertion jig 3 via the conduit 2h.
- the ejection mechanism 6 connected to the insertion jig 3 includes a fixing plate 61, a holding plate 62, a Korgut tube 63, and a clamp 64.
- the fixing plate 61 is fixed to the insertion jig 3 to form an opening 6 a corresponding to the main pipe 31.
- the holding plate 6 2 An end plate 6b corresponding to the fixing plate 61 and a plug 6c integrally formed with the end plate 6b and fitted into the opening 6a of the fixing plate 61 are provided.
- the corrugated pipe 63 is connected to the fixed plate 61 and the holding plate 62 so as to collect excrement.
- the clamp 64 fixes the fixing plate 6 1 and the holding plate 62 to a state in which the stopper 6 c of the holding plate 62 is fitted into the opening 6 a of the fixing plate 61.
- the liquid component of the gas-liquid mixture containing methylcellulose and the like, which is liable to generate air bubbles, is charged, and dry ice for generating a gaseous component is placed in the liquid component. Put in. In this state, the closing valve 5d and the air bleeding valve 5e are closed.
- the piston 52 is inserted into the storage container 51, the excess air is removed by opening the air release valve 5e, and then the air release valve 5e is closed.
- carbon dioxide gas is generated from the dry ice, and this carbon dioxide gas pushes up biston 52.
- the gas component and the liquid component are mixed, and a gas-liquid mixture having a predetermined mixing ratio and volume is generated by measuring the weight.
- the closing valve 5 d is opened and the piston 52 is pressed, and the intestinal cleaning agent of the gas-liquid mixture is injected from the insertion jig 3 into the intestinal tract 1 2. Injected into.
- the clamp 64 is kept attached until a predetermined time elapses after the intestinal cleansing agent is injected. In this state, the contents of the intestinal tract 12 are fluidized and liquefied, but are not excreted.
- the pressing plate 62 retreats, and the internal pressure of the intestinal tract 12 causes natural defecation, and the pressing plate 62 retreats, and the corrugated tube 6 is retracted.
- the contents of the intestinal tract 1 and 2 are recovered.
- the contents of the intestinal tract 12 are reduced by forcibly retracting the holding plate 62 and forcibly expanding the Korgut tube 63. Is sucked, and forced defecation is performed.
- FIGS. 5 and 6 another supply mechanism 7 is provided in place of the supply mechanism 2 of the first embodiment.
- the supply mechanism 7 includes a mixing container 71, a corrugated pipe 72, and a foaming agent container 73.
- a mixing container 71 a mixing space 7a is formed, and a corrugated pipe 72 is connected to an open end of the mixing space 7a. The end of the corrugated pipe 72 is closed with a lid 74.
- the mixing container 71 has a supply passage 7b and a foaming agent passage 7c communicating with the mixing space 7a.
- the supply passage 7b is provided with a closing valve 7d, while the foaming agent passage 7c is fitted with a closing plug 75.
- the supply passage 7b is connected to the insertion jig 3 via a conduit 2h.
- the closure plug 75 is formed in a hollow body having one end opened, and has a communication port 7e penetrating inside and outside at an end. Further, the closing plug 75 is configured so that the foaming agent container 73 is inserted.
- the foaming agent container 73 is configured to be capable of storing a foaming agent, is formed to be insertable into the foaming agent passage 7c, and is formed with a pressing rod 7f that presses the closing plug 75.
- the closing plug 75 is removed, and the bubble kept warm about 37 degrees Celsius is used.
- the liquid component of the gas-liquid mixture containing methylcellulose or the like, which is liable to occur, is stored in the mixing space 7a of the mixing container 71 by a predetermined volume.
- the closing plug 75 is fitted into the foaming agent passage 7c to close the mixing space 7a.
- a foaming agent for example, a foaming agent in which tartaric acid and sodium bicarbonate are finely powdered and mixed is stored in a foaming agent container 73.
- the foaming agent container 73 When the foaming agent container 73 is fitted into the foaming agent passage 7c, as shown in FIG. 6, the closing plug 75 is pushed into the mixing space 7a by the pressing rod 7f, and the communication port 7e is inserted into the mixing space. 7a, the foaming agent mixes with the liquid component of the gas-liquid mixture and foams. When this foaming is started, the corrugated pipe 72 expands, and the gas-liquid mixture fills the mixing space 7a and the inside of the corrugated pipe 72.
- the intestinal cleaning agent of the gas-liquid mixture is injected from the insertion jig 3 into the intestinal tract 1 2. Injected into.
- a simple intestinal cleaning device 1 is used in place of the intestinal cleaning device 1 of the first embodiment, which is a so-called disposable type.
- the intestinal tract cleaning device 1 includes a supply mechanism 8 and an insertion jig 9.
- the supply mechanism 8 includes a bag 81 and a connection plug 82.
- the bag body 81 has a partition wall 83 inside, and an upper chamber 8a and a lower chamber 8b are formed.
- the bag 81 is formed of a flexible member such as a plastic film or a rubber sheet.
- the partition wall 83 is formed of a fragile material, and is configured to be easily broken by an external force.
- the upper chamber 8a contains an acidic liquid which is a liquid component of the gas-liquid mixture, for example, a pod supernatant and lactic acid.
- a foaming agent for example, aqueous sodium bicarbonate is stored in the lower chamber 8b.
- the insertion jig 9 includes a conduit 91 and a closing valve 92 provided in the middle of the conduit 91.
- the conduit 91 is formed in a flexible and elongated shape to be inserted into the intestinal tract 12. Then, the connection plug 8 2 of the supply mechanism 8 is connected to the conduit 9 1 Have been.
- the partition wall 83 of the supply mechanism 8 is broken.
- the bulkhead 83 is broken by manually rubbing the bag 81. Due to this destruction, the upper chamber 8a communicates with the lower chamber 8b, and a gas-liquid mixture containing air bubbles is generated. The intestinal cleansing agent of this gas-liquid mixture fills the inside of the bag 81.
- the insertion jig 9 is inserted into the intestinal tract 12, the closing valve 92 is opened, and the bag 81 is pressed, whereby the intestinal irrigant is injected into the intestinal tract 12.
- the sequence of the above operations may be such that the insertion jig 9 is first inserted into the intestinal tract 12, the closing valve 92 is opened, and then the partition wall 83 is broken.
- the insertion jig 9 is removed, and after a predetermined time has passed, defecation is performed.
- Other configurations, operations, and effects are the same as those of the first or second embodiment.
- the upper chamber 8a may also contain an injection liquid containing a thickener such as methyl cellulose.
- a thickener such as methyl cellulose.
- the present device involves the generation of air bubbles, and useful substances produced by the lactic acid bacteria and the air bubbles are injected into the intestinal tract 12.
- the present embodiment relates to, for example, an intestinal cleaning service using the intestinal cleaning device 1 according to the first embodiment.
- an intestinal washing station located in the city provides services for the general public, including explanations of eating habits.
- the person who wishes to cleanse the body prepares a personal file and fills out the questionnaire with the physical condition and lifestyle. Estheticians will use the health questionnaire to determine the current status of bowel movements. Washing The details and method of treatment will be explained at the time of this counseling, and the understanding and cooperation of those who wish to cleanse the bowel will be obtained.
- the practitioner will guide the applicant to the treatment room (private room) and change into a special gown. If you wish, urinate with the toilet in the treatment room and weigh yourself.
- the person who wants to cleanse the body is turned on the treatment table, and the person who cleans the bowel massages the entire colon.
- intestinal lavage bubble cleansing
- the person who wants to cleanse bows, laying down on the left side, and takes the Sims position, bending his right knee toward his chest.
- the intestine cleanser applies a lubricant to the insertion jig 3 of the special intestinal tract 12 and gently inserts it into the rectum of the desired intestine by about 5 to 6 cm. Attach the discharge tube 4 1 to the insertion jig 3 and the person who wants to cleanse the body again takes a back-up posture.
- the gastrointestinal lavage injected from the rectum flows through the descending colon and into the ascending colon.
- the injection temperature is set at around 37 ° C, and the gastrointestinal cleaning agent controlled by this device flows into the intestinal tract 12 slowly and gently. This injection and discharge should be about 5 minutes per cycle.
- the gastrointestinal lavage which has flowed through the intestinal tract 12 while fluidizing the feces, flows out of the discharge tube 41 together with the waste in the intestinal tract 12. This injection, washing and draining cycle is repeated several times to thoroughly wash the entire intestine.
- the remaining intestinal cleanser and stool are drained from a dedicated toilet provided in the treatment room, and grooming is performed.
- S 9 Give end counseling for intestinal irrigation.
- the esthetician checks the health of the person who wishes to cleanse the bowel, and ends the procedure. After that, the bowel washer, etc. stores the personal file in the storage at the exit cashier, pays the disposal fee, and returns home.
- Pectin polyvinylinoleanolone, methinoresenololose, canoleboximetinolenoleose, polyacryloline sodium acid, anolebumin, sugar estenole, glycerin fatty acid ester, kuzu, sucrose and at least a commercial neutral detergent Either was an aqueous solution.
- bubble formation by a mixer (2) bubble formation by a foaming device and injection into a pipe, (3) introduction of dry ice into a solution and generation of bubbles into a connected pipe Regarding the inflow and (4) injection of foamed C02 with tartaric acid and baking soda into the solution, the size, strength and time-life of bubbles were evaluated.
- the obtained results were evaluated according to the following evaluation criteria, and the results shown in FIG. 9 were obtained.
- the five criteria for bubble formation evaluation in Fig. 9 are: large amount of bubbles generated, four points of medium bubbles generated, three points of small bubbles generated, and two points of slight bubbles generated. Occurrence, 1 point indicates that almost no bubbles are observed.
- a of the evaluation criteria for the duration of the bubble indicates that the duration lasted for 15 minutes or more, A indicates that the duration was less than 15 minutes, and BB indicates that the duration was less than 5 minutes.
- Example 2 With respect to the fluidization of hardened stool of the present invention, the addition of any of methylcellulose, sugar ester, polyglycerol, polyvinyl alcohol, yogurt supernatant, cluster dextrin and vectin to the excreted feces was tested. The cured stool was dispersed and fluidized when any of the solutions was added except for sodium bicarbonate. In particular, rapid liquefaction was achieved for sugar esters and polydali esters.
- AAA which is a standard for evaluating the mobilization of human discharged feces, indicates rapid mobilization, AA indicates mobilization within 5 minutes, and A indicates satisfactory mobilization within 5 minutes.
- B indicates no fluidization, B indicates no fluidization.
- AA of the evaluation standard of the bubble strength in the model intestinal tract 12 in FIG. 11 indicates a bubble layer of 20 cm or more
- A indicates a bubble layer of 20 to 10 cm
- BB indicates 1 Shows a bubble layer of less than 0 cm.
- the body cavity includes the nasal cavity, ear cavity, eustachian tube, oral cavity, trachea, bronchi, esophagus, stomach, duodenum, small intestine, gallbladder, bile duct, Teng tube, spinal canal, subdural space, thoracoabdominal cavity, pericardial cavity , Mediastinum, renal pelvis, ureter, vesicoureteral cavity, utero-vaginal cavity, joint cavity, abscess cavity, infected foci, abscess and vascular cavity.
- a foam-like object is used as the gas-liquid mixture.
- a vapor in which a liquid component is suspended in a gas component may be used.
- the gas-liquid mixture only needs to be a mixture of at least a gas component and a liquid component.
- the body cavity cleansing agent, the body cavity cleaning device, and the body cavity cleansing method according to the present invention are useful for cleaning a body cavity, particularly useful for excretion of fecal matter, and various defecations. Suitable for disabilities.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002510623A CA2510623A1 (en) | 2002-12-09 | 2003-12-09 | Body cavity washer, device for washing body cavity and method of washing body cavity |
AU2003289279A AU2003289279A1 (en) | 2002-12-09 | 2003-12-09 | Body cavity washer, device for washing body cavity and method of washing body cavity |
JP2004558448A JP4283772B2 (ja) | 2002-12-09 | 2003-12-09 | 洗浄剤及び洗浄装置 |
EP03777416A EP1593375A1 (en) | 2002-12-09 | 2003-12-09 | Body cavity washer, device for washing body cavity and method of washing body cavity |
US10/538,090 US20060034939A1 (en) | 2002-12-09 | 2003-12-09 | Body cavity washer, device for washing body cavity and method of washing body cavity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-383148 | 2002-12-09 | ||
JP2002383148 | 2002-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004052338A1 true WO2004052338A1 (ja) | 2004-06-24 |
Family
ID=32501162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015747 WO2004052338A1 (ja) | 2002-12-09 | 2003-12-09 | 生体腔洗浄剤、生体腔洗浄装置および生体腔洗浄方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060034939A1 (ja) |
EP (1) | EP1593375A1 (ja) |
JP (1) | JP4283772B2 (ja) |
AU (1) | AU2003289279A1 (ja) |
CA (1) | CA2510623A1 (ja) |
WO (1) | WO2004052338A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026444A1 (fr) * | 2006-08-28 | 2008-03-06 | Miyarisan Pharmaceutical Co., Ltd. | Aide à l'irrigation du tractus gastro-intestinal comprenant des bactéries butyriques et/ou des bactéries lactiques |
WO2013122125A1 (ja) * | 2012-02-14 | 2013-08-22 | 国立大学法人東北大学 | ウォータージェット噴射ノズル、ウォータージェット噴射装置、消化管洗浄装置及び胃壁洗浄装置 |
WO2013187407A1 (ja) * | 2012-06-15 | 2013-12-19 | 大研医器株式会社 | 洗浄液、及び洗浄方法 |
JP2016508498A (ja) * | 2013-10-17 | 2016-03-22 | カン, ユンシクKANG, YoonSik | 腸洗浄用組成物 |
JP2019115672A (ja) * | 2013-12-22 | 2019-07-18 | モータス ジーアイ メディカル テクノロジーズ リミテッド | 結腸を洗浄するための装置 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025729A1 (en) * | 2004-07-30 | 2006-02-02 | Leiboff Arnold R | Transanal colorectal irrigators |
ITRM20070349A1 (it) * | 2007-06-22 | 2008-12-23 | Mario Loddo | Apparecchiatura per la rimozione di ostruzioni intestinali. |
EP2716311A1 (en) * | 2012-09-19 | 2014-04-09 | Jose Hernandez Mondejar | Disposable device for internal anal canal hygiene |
CN105381517B (zh) * | 2015-12-14 | 2019-04-12 | 北京大学深圳医院 | 消化内科用通便器 |
CN111359045A (zh) * | 2020-03-18 | 2020-07-03 | 吉林大学 | 一种带有冲洗装置的泌尿科用护理装置 |
CN115135257A (zh) | 2020-04-08 | 2022-09-30 | 波士顿科学国际有限公司 | 具有球囊和提取构件的医疗器械 |
CN111514446B (zh) * | 2020-06-05 | 2021-04-27 | 吉林大学 | 一种耳鼻喉科护理用鼻腔部上药装置 |
CN113712623B (zh) * | 2021-09-14 | 2023-01-24 | 王艳 | 一种肛肠科临床术后镇痛止血装置 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11319082A (ja) * | 1998-05-14 | 1999-11-24 | Terumo Corp | 腸内固形物分離用具および洗腸装置 |
JPH11324070A (ja) * | 1998-05-14 | 1999-11-26 | Matsushita Electric Ind Co Ltd | 人体局部洗浄装置 |
JP2000070327A (ja) * | 1998-09-01 | 2000-03-07 | Kao Corp | 鼻腔内洗浄具 |
EP1044699A1 (en) * | 1997-10-17 | 2000-10-18 | MEFAR S.p.A. | Apparatus for washing the nasal cavities |
JP2001354549A (ja) * | 2000-06-08 | 2001-12-25 | Koike Kagaku Kk | 鼻腔洗浄エアゾール製品 |
JP2003040766A (ja) * | 2001-07-26 | 2003-02-13 | Kao Corp | 鼻腔内洗浄具 |
-
2003
- 2003-12-09 EP EP03777416A patent/EP1593375A1/en not_active Withdrawn
- 2003-12-09 US US10/538,090 patent/US20060034939A1/en not_active Abandoned
- 2003-12-09 WO PCT/JP2003/015747 patent/WO2004052338A1/ja active Application Filing
- 2003-12-09 CA CA002510623A patent/CA2510623A1/en not_active Abandoned
- 2003-12-09 AU AU2003289279A patent/AU2003289279A1/en not_active Abandoned
- 2003-12-09 JP JP2004558448A patent/JP4283772B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1044699A1 (en) * | 1997-10-17 | 2000-10-18 | MEFAR S.p.A. | Apparatus for washing the nasal cavities |
JPH11319082A (ja) * | 1998-05-14 | 1999-11-24 | Terumo Corp | 腸内固形物分離用具および洗腸装置 |
JPH11324070A (ja) * | 1998-05-14 | 1999-11-26 | Matsushita Electric Ind Co Ltd | 人体局部洗浄装置 |
JP2000070327A (ja) * | 1998-09-01 | 2000-03-07 | Kao Corp | 鼻腔内洗浄具 |
JP2001354549A (ja) * | 2000-06-08 | 2001-12-25 | Koike Kagaku Kk | 鼻腔洗浄エアゾール製品 |
JP2003040766A (ja) * | 2001-07-26 | 2003-02-13 | Kao Corp | 鼻腔内洗浄具 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026444A1 (fr) * | 2006-08-28 | 2008-03-06 | Miyarisan Pharmaceutical Co., Ltd. | Aide à l'irrigation du tractus gastro-intestinal comprenant des bactéries butyriques et/ou des bactéries lactiques |
JP2008050325A (ja) * | 2006-08-28 | 2008-03-06 | Miyarisan Pharmaceutical Co Ltd | 酪酸菌及び/又は乳酸菌を含有してなる消化管洗浄助剤 |
JP4572185B2 (ja) * | 2006-08-28 | 2010-10-27 | ミヤリサン製薬株式会社 | 酪酸菌及び/又は乳酸菌を含有してなる消化管洗浄助剤 |
WO2013122125A1 (ja) * | 2012-02-14 | 2013-08-22 | 国立大学法人東北大学 | ウォータージェット噴射ノズル、ウォータージェット噴射装置、消化管洗浄装置及び胃壁洗浄装置 |
JPWO2013122125A1 (ja) * | 2012-02-14 | 2015-05-18 | 国立大学法人東北大学 | ウォータージェット噴射ノズル、ウォータージェット噴射装置、消化管洗浄装置及び胃壁洗浄装置 |
WO2013187407A1 (ja) * | 2012-06-15 | 2013-12-19 | 大研医器株式会社 | 洗浄液、及び洗浄方法 |
JP2014000160A (ja) * | 2012-06-15 | 2014-01-09 | Takeshi Ohira | 洗浄液、及び洗浄方法 |
JP2016508498A (ja) * | 2013-10-17 | 2016-03-22 | カン, ユンシクKANG, YoonSik | 腸洗浄用組成物 |
US10973808B2 (en) | 2013-10-17 | 2021-04-13 | Yoon Sik Kang | Bowel cleansing composition |
JP2019115672A (ja) * | 2013-12-22 | 2019-07-18 | モータス ジーアイ メディカル テクノロジーズ リミテッド | 結腸を洗浄するための装置 |
US11484632B2 (en) | 2013-12-22 | 2022-11-01 | Motus Gi Medical Technologies Ltd. | Colon cleaning devices and methods |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004052338A1 (ja) | 2006-04-06 |
EP1593375A1 (en) | 2005-11-09 |
US20060034939A1 (en) | 2006-02-16 |
AU2003289279A1 (en) | 2004-06-30 |
JP4283772B2 (ja) | 2009-06-24 |
CA2510623A1 (en) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4283772B2 (ja) | 洗浄剤及び洗浄装置 | |
US4682979A (en) | Colon washing methods and apparatus | |
US11089923B2 (en) | Advanced hygienic excreta system | |
JP2003520066A5 (ja) | ||
JP2003520066A (ja) | オストミー洗浄装置 | |
CN111132670A (zh) | 具有增强的渗透的药物组合物 | |
CN108309484B (zh) | 用于口腔科的便携式口腔清洁喷洗设备 | |
TW200930385A (en) | Composition with active ingredient combination for the treatment of constipation | |
JPH08131538A (ja) | 排便処理装置 | |
US11583147B2 (en) | Advanced hygienic excreta system | |
CN201045209Y (zh) | 一种防溅除臭坐厕 | |
US20110067728A1 (en) | Method and apparatus for personal hygiene | |
CN212730579U (zh) | 一种消化内科用的灌肠装置 | |
CN105908818B (zh) | 一种专供便秘人使用的马桶装置 | |
CN201135639Y (zh) | 一种便通器 | |
CN209474490U (zh) | 一种多功能臀部清洗装置 | |
CN215740411U (zh) | 一种新型肛肠疾病患者用清洁坐浴盆 | |
CN104884070B (zh) | 盐和糖的混合物在制备用于治疗哺乳动物的阴道松弛综合征或阴道干燥疾病的药物中的用途 | |
CN2753725Y (zh) | 多束射流喷射臭氧水即生即用气液混合器 | |
CN211962719U (zh) | 一种用于普外科灌肠用辅助装置 | |
CN219043040U (zh) | 灌肠管固定器 | |
CN207253357U (zh) | 排毒通便器 | |
JP2003180763A (ja) | 洗浄機構付泌尿器 | |
WO2008043239A1 (fr) | Dispositifs médicaux ou de confort permettant un traitement hydrothérapeutique présentant une application gynécologique et andrologique, à utiliser dans des pièces de type salle de bains | |
CN201537272U (zh) | 家用肠道水疗仪 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004558448 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006034939 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2510623 Country of ref document: CA Ref document number: 10538090 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003777416 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003777416 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10538090 Country of ref document: US |